+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists



Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists



Journal of Biological Chemistry 276(27): 25366-25371



Although agonist binding in adrenergic receptors is fairly well understood and involves residues located in transmembrane domains 3 through 6, there are few residues reported that are involved in antagonist binding. In fact, a major docking site for antagonists has never been reported in any G-protein coupled receptor. It has been speculated that antagonist binding is quite diverse depending upon the chemical structure of the antagonist, which can be quite different from agonists. We now report the identification of two phenylalanine residues in transmembrane domain 7 of the alpha(1a)-adrenergic receptor (Phe-312 and Phe-308) that are a major site of antagonist affinity. Mutation of either Phe-308 or Phe-312 resulted in significant losses of affinity (4-1200-fold) for the antagonists prazosin, WB4101, BMY7378, (+) niguldipine, and 5-methylurapidil, with no changes in affinity for phenethylamine-type agonists such as epinephrine, methoxamine, or phenylephrine. Interestingly, both residues are involved in the binding of all imidazoline-type agonists such as oxymetazoline, cirazoline, and clonidine, confirming previous evidence that this class of ligand binds differently than phenethylamine-type agonists and may be more antagonist-like, which may explain their partial agonist properties. In modeling these interactions with previous mutagenesis studies and using the current backbone structure of rhodopsin, we conclude that antagonist binding is docked higher in the pocket closer to the extracellular surface than agonist binding and appears skewed toward transmembrane domain 7.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046973072

Download citation: RISBibTeXText

PMID: 11331292

DOI: 10.1074/jbc.m103152200


Related references

Phe-308 and Phe-312 in transmembrane domain 7 are major sites of a1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists. The Journal of Biological Chemistry 276(27): 366-71, 2001

Asp125 and Thr130 in Transmembrane Domain 3 Are Major Sites of α1b-Adrenergic Receptor Antagonist Binding. Biological & Pharmaceutical Bulletin 30(10): 1891-1894, 2007

Asp125 and Thr130 in transmembrane domain 3 are major sites of alpha1b-adrenergic receptor antagonist binding. Biological and Pharmaceutical Bulletin 30(10): 1891-1894, 2007

Modulation of binding by guanine nucleotide suggests that antagonists and agonists bind to different forms of an alpha 2 adrenergic receptor on human platelets. Society for Neuroscience Abstracts 10(1): 280, 1984

Probing the Binding Domain of the NK2 Receptor with Fluorescent Ligands: Evidence That Heptapeptide Agonists and Antagonists Bind Differently. Biochemistry 34(12): 3972-3980, 1995

Adrenergic Agonists Bind to Adrenergic-Receptor-Like Regions of the Mu Opioid Receptor, Enhancing Morphine and Methionine-Enkephalin Binding: A New Approach to "Biased Opioids"?. International Journal of Molecular Sciences 19(1):, 2018

3H]Rilmenidine-labelled imidazoline-receptor binding sites co-localize with [3H]2-(benzofuranyl)-2-imidazoline-labelled imidazoline-receptor binding sites and monoamine oxidase-B in rabbit, but not rat, kidney. Journal of the Autonomic Nervous System 72(2-3): 118-128, 1998

A single point mutation in the seventh hydrophobic domain of the alpha 2-adrenergic receptor changes antagonist binding specificity to that of a beta receptor. Transactions of the Association of American Physicians 104: 62-68, 1991

Comparison of the binding activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig. Pharmacology and Toxicology 76(6): 353-364, 1995

Rilmenidine-labelled imidazoline-receptor binding sites co-localize with 2- -2-imidazoline-labelled imidazoline-receptor binding sites and monoamine oxidase-B in rabbit, but not rat, kidney. Journal of the Autonomic Nervous System 72(2-3): 118-128, 1998

Interaction of subtype-selective antagonists with alpha 1-adrenergic receptor binding sites in rat tissues. Molecular Pharmacology 40(4): 531-538, 1991

Do agonists and competitive antagonists bind to distinct sites on the nmda receptor. Cavalheiro, E A , J Lehmann And L Turski (Ed ) Neurology And Neurobiology, Vol 46 Frontiers in Excitatory Amino Acid Research; International Symposium Excitatory Amino Acids '88, Manaus, Amazonas, Brazil, March 28-April 2, Xxxvi+745p Alan R Liss, Inc : New York, New York, Usa Illus 59-66, 1988

Interaction of imidazoline alpha-adrenergic receptor antagonists with histamine receptors. Journal of Cardiovascular Pharmacology 1(6): 633-640, 1979

Differences in imidazoline and phenylethylamine alpha-adrenergic agonists: comparison of binding affinity and phosphoinositide response. Neuropharmacology 30(7): 745-751, 1991

Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain. Brain Research 514(1): 15-21, 1990